

# Cancer Cachexia Market Epidemiology Report 2025-2035: Pipeline Therapies, Drugs Sales, and Regional Outlook

*The report also provides a detailed analysis of the current Cancer cachexia marketed drugs and late-stage pipeline drugs.*

BROOKLYN, NY, UNITED STATES, July 14, 2025 /EINPresswire.com/ -- According to the latest report by IMARC Group, the [cancer cachexia market is expected to exhibit a CAGR of 3.65%](#) during 2025-2035. Cachexia is a deficitary syndrome associated with cancer characterized by an advanced state of nutritional imbalance resulting in excessive weight loss and muscle atrophy alongside a deterioration in health. This presents a significant burden for oncology patients, particularly those with advanced stages of the malignancy. The condition has far-reaching implications on the patient's quality of life, treatment response, and survival metrics. In the context of research and other therapeutic developments, the evolution of the cancer cachexia market is accelerating as we near 2025.



Cancer Cachexia Market Epidemiology Report 2025-2035: Pipeline Therapies, Drugs Sales, and Regional Outlook

Perhaps the most important change in the cancer cachexia market is the increasing awareness of the syndrome by both the healthcare professionals and the patients themselves. In the past, cancer-cachexia syndrome was given little attention and was brushed off as a complication that accompanies cancer. They are realizing that it is now important to manage cachexia as a syndrome of its own, absent cancer, and its management is essential on its own. The paradigm shift in understanding the syndrome has catalyzed greater awareness as well as timely intervention and management which improves outcomes.

Technological advancements and associated research activities are significantly contributing to the growth of the cancer cachexia market. Researchers are attempting to unravel the various mechanisms responsible for cachexia, especially the role inflammatory cytokines, metabolism, and hormonal changes play. This understanding is aiding in the formulation of new therapeutic strategies to reduce the impacts of cachexia. For example, some researchers are studying the use of anti-inflammatory drugs, or compounds designed to preserve muscle tissue and stimulate

appetite, by targeting relevant metabolic processes in cancer patients.

Request to get a PDF Sample Report: <https://www.imarcgroup.com/cancer-cachexia-market-report/requestsamplereport>

A broadening array of treatment options is being developed for cancer cachexia that includes both pharmacological and non-pharmacological methods. The longstanding nutritional therapy and appetite stimulants should still be used. There is increasing attention being given to the use of exercise and movement as part of the treatment. Research shows that specific exercises can combat muscle wasting and enhance the well-being of cancer patients. This comprehensive approach in the management of cachexia is growing in popularity and will be adopted into treatment protocols in the near future.

The escalating rate of collaboration among pharmaceutical firms, educational divisions, and practitioners represents a significant shift in the market of cancer cachexia. Since collaborative research is deemed indispensable for advancing the understanding of cachexia and creating new treatments, these collaborations facilitate innovation and speed up the development of novel therapies to meet the ever-evolving demands of cancer cachexia. An increase in investment is anticipated now that more stakeholders are recognizing the importance of this syndrome and its relevance in research and development.

The cancer cachexia market is also witnessing the rise of personalized medicine. The creation of individual treatment strategies for each patient is becoming increasingly practical. Cachexia interventions can be tailored more effectively considering the cancer type, stage, and even patient preferences. Enhanced adherence and improved outcomes are expected as a consequence of this customized approach.

In addition, the rising incidence of cancer globally is increasing the need for efficient management strategies for cachexia. With the escalating number of cancer cases, the associated cachexia burden will also rise, making it increasingly imperative to devise breakthrough therapies. It is expected that in addressing this unfulfilled promise, pharmaceutical firms will allocate significant resources in research and development, thereby enlarging the cancer cachexia business.

Buy the full Cancer Cachexia Market Epidemiology Report with TOC:  
<https://www.imarcgroup.com/checkout?id=9224&method=809>

This report also provides a detailed analysis of the current Cancer cachexia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

#### Late-Stage Pipeline Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

#### Competitive Landscape With Key Players:

The competitive landscape of the cancer cachexia market has been studied in the report with the detailed profiles of the key players operating in the market.

AVEO Pharmaceuticals, Inc.  
Endevica Bio  
NGM Biopharmaceuticals

Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

#### 7 Major Countries Covered

United States  
Germany  
France  
United Kingdom  
Italy  
Spain  
Japan

#### IMARC Group Offers Other Reports:

Type 2 Diabetes Market [https://world.einnews.com/pr\\_news/820405295/type-2-diabetes-market-size-in-the-7mm-is-estimated-to-exceed-usd-42-8-billion-by-2035](https://world.einnews.com/pr_news/820405295/type-2-diabetes-market-size-in-the-7mm-is-estimated-to-exceed-usd-42-8-billion-by-2035)

ANCA Vasculitis Market <https://www.einpresswire.com/article/820354434/anca-vasculitis-market-size-epidemiology-trends-treatment-and-forecast-2025-2035>

Erectile Dysfunction Market [https://www.einnews.com/pr\\_news/820367642/erectile-](https://www.einnews.com/pr_news/820367642/erectile-)

[dysfunction-market-size-to-reach-usd-4-5-billion-by-2035-epidemiology-report-by-imarc-group](#)

hemophilia A market <https://www.einpresswire.com/article/821434221/hemophilia-a-market-epidemiology-report-2025-2035-drug-pipeline-treatment-trends-rising-incidence-prevalence>

Agoraphobia Market <https://www.einpresswire.com/article/821443845/agoraphobia-market-epidemiology-report-2025-2035-drug-pipeline-treatment-trends-rising-incidence-prevalence>

Autism Spectrum Disorder Market <https://www.einpresswire.com/article/822691290/autism-spectrum-disorder-market-size-therapeutics-trends-and-rising-global-prevalence-2025-2035>

Elena Anderson

IMARC Services Private Limited

+1 631-791-1145

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/830529414>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.